Empty vials of the Pfizer COVID-19 vaccine are seen at a drive-through vaccination facility operated by the Lake County Health Department in Groveland, Florida on January 28, 2021.
Paul Hennessy | NurPhoto | Getty Images
Pfizer expects to sell around $ 15 billion worth of coronavirus vaccine doses this year, the company said when it released its fourth quarter earnings on Tuesday.
The company’s Covid-19 vaccine, which it produces together with German partner BioNTech, was the first to be approved for use in the United States. For this year, sales were forecast to be between $ 59.4 billion and $ 61.4 billion.
According to Refinitiv’s average estimates, Pfizer performed in the fourth quarter compared to Wall Street expectations.
- Adjusted EPS: 42 cents versus 48 cents, expected.
- Revenue: $ 11.68 billion versus $ 11.43 billion expected.
Revenue rose 12% from $ 10.44 billion in the same quarter last year to $ 11.68 billion – better than analysts expected.
Pfizer’s shares were largely unchanged in premarket trading.
“As a company, we have seen the culmination of decades in Pfizer’s transformation into a pure science and innovation-driven company,” said Albert Bourla, Pfizer CEO, in a press release. “Our ability to move forward quickly and use the latest science to address the world’s major medical challenges has been tested by the COVID-19 pandemic.”
Pfizer, like other Covid-19 vaccine manufacturers, is struggling to meet demand for shots that will help end the pandemic. Pfizer expects to ship 200 million doses of its two-shot vaccine to the US by July 31. The company recently asked the French pharmaceutical company Sanofi for help with the manufacture of cans.
This is a developing story. Please try again.